Corrigendum to “Co-delivery of VP-16 and Bcl-2-targeted antisense on PEG-grafted oMWCNTs for synergistic in vitro anti-cancer effects in non-small and small cell lung cancer”

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216305%3A26620%2F22%3APU144066" target="_blank" >RIV/00216305:26620/22:PU144066 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Corrigendum to “Co-delivery of VP-16 and Bcl-2-targeted antisense on PEG-grafted oMWCNTs for synergistic in vitro anti-cancer effects in non-small and small cell lung cancer”
Original language description
Present study describes the preparation of a polyethylene glycol-grafted oxidized multi-walled carbonnanotubes (oMWCNTs-PEG) hybrid nanosystem as a carrier of etoposide (VP-16) and Bcl-2 phosphoroth-ioate antisense deoxyoligonucleotides (Aso) to achieve a superior cytostastic efficacy in non-small andsmall cell lung cancer in vitro. We have demonstrated that the adsorption of hydrophobic VP-16 and Bcl-2Aso results in a stable nanotransporter exhibiting good dispersion with excellent release profiles (both,in pH 7.4 and 4.8) and negligible hemolytic activity (up to 6.5%). The evaluation of cytotoxicity was car-ried out in in vitro using small cell (SCLC; DMS53) and non-small cell lung cancer (NSCLC; NCIH2135) celllines. It was found that Bcl-2 interference significantly increased the anti-cancer efficiency of VP-16 in thechemoresistant NSCLC cells. This was further supported using a flow-cytometry (Annexin V/propidiumiodide assay), which revealed a significant increase in apoptotic cells in both the ce
Czech name
—
Czech description
—

Project
<a href="/en/project/LQ1601" target="_blank" >LQ1601: CEITEC 2020</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)